Source study found

Story checked

New Antibody Treatment Silences Nerve Pain for Days Without Blocking Normal Pain (opens in a new tab)

scitechdaily.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

4 supported
5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

New Antibody Treatment Silences Nerve Pain for Days Without Blocking Normal Pain

scitechdaily.com · 2026-10-05

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Four of nine claims match the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

4 supported
5 not covered

Open claim evidence

The source study

A Systemically Administered Humanized Anti-Nav1.7 Antibody with Long-Lasting Analgesic Activity and Preserved Physiological Nociception

Pharmaceutics · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

9 claims in this story

Showing all 9 claimsChoose a verdict to focus the list.

Claim 1 of 9Not coveredClone1 and S-151128 bound strongly to Nav1.7 and reduced electrical activity associated with pain signaling; Clone1 showed at least 650-fold selectivity and S-151128 at least 1300-fold selectivity over the other Nav subtypes tested.View evidenceHide evidence

As statedat least 650-fold selectivity; at least 1300-fold selectivity

Why this verdict

The abstract-level profile supports high-affinity, selective Nav1.7 binding and functional inhibition, and separately reports reduced neuronal activity. However, it does not provide clone-specific names, exact selectivity ratios, or the detailed quantitative comparisons stated for Clone1 and S-151128. Those details cannot be verified from the supplied abstract-depth profile.

Study evidence

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.

Study evidence

Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after systemic administration of the humanized anti-Nav1.7 antibody in PSNL rats.

Claim 2 of 9Not coveredIn rats with partial sciatic nerve ligation, both antibodies reduced sensitivity to mechanical stimulation in a dose-dependent manner, and at some doses their effects were comparable to pregabalin.View evidenceHide evidence

As stateddose-dependent; comparable to pregabalin

Why this verdict

The profile supports analgesic efficacy in the rat PSNL model, but the abstract-level evidence does not state that both antibodies reduced mechanical sensitivity, that the response was dose-dependent, or that effects were comparable to pregabalin at some doses.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 3 of 9Not coveredAfter 96 hours, pain relief from the antibodies remained stronger than the effect produced by pregabalin.View evidenceHide evidence

As stated96 hours

Why this verdict

The profile states that the lead antibody produced analgesia lasting at least 96 hours, but it does not provide a 96-hour comparison with pregabalin or support the claim that antibody pain relief remained stronger than pregabalin at that timepoint.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 4 of 9Not coveredIn animals without nerve injury, none of the antibodies significantly changed responses to mechanical stimulation, and the antibodies did not significantly affect motor function on a rotating-rod task.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the broad conclusion that physiological nociception and motor function were not impaired under tested conditions. It does not verify the more specific details that animals without nerve injury had no significant mechanical-response changes, that none of the antibodies had such effects, or that motor function was assessed specifically on a rotating-rod task.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 5 of 9Not coveredThe findings remain preclinical, the authors could not accurately determine how much antibody reached the injured nerve, and the treatment was evaluated in only one neuropathic pain model.View evidenceHide evidence

Why this verdict

The profile supports the preclinical nature of the evidence and that it comes from a rat PSNL neuropathic pain model, so translatability is limited. But the supplied abstract-depth profile does not state that the authors could not accurately determine how much antibody reached the injured nerve; that caveat is not verifiable from the supplied evidence.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 6 of 9SupportedA new antibody-based approach may be able to suppress abnormal nerve pain without dulling the body’s normal warning signals.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a preclinical, hedged claim that anti-Nav1.7 antibodies may suppress neuropathic pain while preserving normal nociception: systemic lead antibody dosing produced long-lasting analgesia in PSNL rats, and physiological nociception and motor function were not impaired under tested conditions.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 7 of 9SupportedIn a new preclinical study, researchers found that antibodies targeting Nav1.7 could suppress abnormal pain signals in rats for days while leaving normal protective pain sensation largely intact.View evidenceHide evidence

As statedfor days

Why this verdict

The paper profile reports robust analgesia lasting at least 96 hours after systemic administration in a rat PSNL neuropathic pain model, with no impairment of physiological nociception or motor function under tested conditions. The claim is framed as a preclinical rat finding, which matches the abstract-level evidence.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 8 of 9SupportedThe experimental antibodies target Nav1.7, a voltage-gated sodium channel found in sensory neurons that helps generate and transmit electrical signals involved in pain.View evidenceHide evidence

Why this verdict

The profile identifies Nav1.7 as a voltage-gated sodium channel and a genetically validated regulator of pain sensation, and the paper evaluates Nav1.7 channel inhibition and sensory-neuron pain-related outcomes. The story’s background description is consistent with the supplied profile.

Study evidence

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Claim 9 of 9SupportedOne of the antibodies, S-151128, is already in clinical trials.View evidenceHide evidence

Why this verdict

The profile notes clinical advancement of S-151128 in the discussion of translational potential. This supports the story’s statement that S-151128 is already in clinical development/trials at the level represented in the profile.

Study evidence

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Immunohistochemistry showed decreased mechanical stimulus-induced pERK in dorsal root ganglion neurons after antibody treatment.
This biomarker/mechanistic result is present in the paper profile but is not mentioned in the story presentation.
From DRG immunohistochemistry for stimulus-induced pERK after systemic antibody treatment in PSNL rats

6 things the story did carry across

The paper generated and humanized monoclonal antibodies targeting Nav1.7 and characterized high-affinity, subtype-selective binding and functional Nav1.7 inhibition in cellular assays.
Systemic administration of a lead humanized anti-Nav1.7 antibody produced robust, long-lasting analgesia lasting at least 96 hours in a rat PSNL neuropathic pain model.
The paper reports preservation of physiological nociception and motor function under the tested conditions, not a comprehensive demonstration of safety or universal preservation of all protective pain responses.
Electrophysiological analyses showed reduced mechanically evoked and spontaneous neuronal activity after antibody treatment in PSNL rats.
The evidence is preclinical and derived from a rat PSNL neuropathic pain model; translatability to humans is not established by this report.
Clinical advancement of S-151128 is noted as part of the translational context.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDemonstrate that systemic dosing of a lead humanized anti-Nav1.7 antibody produces robust, long-lasting analgesia in a rat neuropathic pain model while preserving physiological nociception and motor function.In vivo rat PSNL neuropathic pain model; systemic antibody administrationExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) neuropathic pain model, systemic administration of a lead humanized anti-Nav1.7 monoclonal antibody produced robust analgesia that lasted at least 96 hours. Electrophysiology showed reduced mechanically evoked and spontaneous neuronal activity, and immunohistochemistry demonstrated decreased mechanical stimulus–induced phosphorylation of ERK in dorsal root ganglion neurons. Under the tested conditions, the antibodies did not impair physiological nociception or motor function. These findings are presented as preclinical proof-of-concept for a long-acting, systemically delivered anti-Nav1.7 biologic analgesic.

Key findings

Systemic administration of the lead humanized anti-Nav1.7 antibody produced robust analgesia in PSNL rats lasting at least 96 hours.
Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after antibody treatment.

What this piece can’t prove

Evidence is preclinical and derived from a rat PSNL model; translatability to humans is not established in this report.
Abstract does not provide numerical effect sizes, sample sizes, dosing regimen, or statistical analyses.

2 further details could not be confirmed from the summary.

2in vitroDevelop and humanize monoclonal antibodies that selectively bind Nav1.7 and inhibit Nav1.7 channel function in cellular systems.in vitro antibody generation and functional characterizationExpand

In plain English

The paper reports generation and humanization of monoclonal antibodies directed against Nav1.7 and in vitro characterization showing high-affinity, subtype-selective binding to Nav1.7 and functional inhibition of Nav1.7 channel activity in cell-based assays.

Key findings

Humanized monoclonal antibodies showed high-affinity binding to Nav1.7 and were reported to be selective for Nav1.7 versus other voltage-gated sodium channel subtypes.
Humanized antibodies functionally inhibited Nav1.7 channel activity in cellular assays.

What this piece can’t prove

The abstract does not specify the exact cell-based assay formats or controls used to demonstrate functional inhibition.

2 further details could not be confirmed from the summary.

3in vivo animalShow mechanistic/biomarker and neurophysiologic correlates of analgesia in vivo (reduced evoked/spontaneous neuronal activity; reduced stimulus-induced pERK in DRG neurons).In vivo electrophysiology and immunohistochemistry in PSNL ratsExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) model of neuropathic pain, systemic administration of a humanized anti-Nav1.7 monoclonal antibody was associated with reduced mechanically evoked and spontaneous neuronal activity measured by electrophysiology, and with decreased mechanical stimulus–induced phosphorylation of ERK in dorsal root ganglion neurons (immunohistochemistry). The abstract reports these neurophysiologic and biomarker changes alongside preserved physiological nociception and motor function.

Key findings

Electrophysiological analyses demonstrated reduced mechanically evoked and spontaneous neuronal activity after systemic administration of the humanized anti-Nav1.7 antibody in PSNL rats.
Immunohistochemistry showed decreased mechanical stimulus–induced phosphorylation of ERK (pERK) in dorsal root ganglion neurons after antibody treatment.

What this piece can’t prove

4 further details could not be confirmed from the summary.

4ex vivo animalShow mechanistic/biomarker and neurophysiologic correlates of analgesia in vivo (reduced evoked/spontaneous neuronal activity; reduced stimulus-induced pERK in DRG neurons).DRG immunohistochemistry for stimulus-induced pERK after systemic antibody treatment in PSNL ratsExpand

In plain English

In a rat partial sciatic nerve ligation (PSNL) neuropathic pain model, systemic administration of a humanized anti-Nav1.7 antibody was associated with reduced mechanical stimulus–induced phosphorylation of extracellular signal-regulated kinase (pERK) in dorsal root ganglion (DRG) neurons measured by immunohistochemistry (reported in the paper abstract). Quantitative details and assay parameters are not provided in the abstract.

Key findings

Systemic administration of the lead humanized anti-Nav1.7 antibody was reported to reduce mechanically evoked phosphorylation of ERK (pERK) in DRG neurons from PSNL rats, as measured by immunohistochemistry.

What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer